Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt.
Central Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt.
Vaccine. 2022 Jul 30;40(32):4303-4306. doi: 10.1016/j.vaccine.2022.05.086. Epub 2022 Jun 6.
The diversity of SARS-CoV-2 continues to lead to the emergence of new SARS-CoV-2 variants. SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic by determining the neutralizing antibody response. This study aims to investigate vaccine-induced antibodies against most common variants of SARS-CoV-2 in Egypt. Sera samples were collected from vaccinated participants and neutralizing activity against the SARS-CoV-2 variants was determined using microneutralization assay. Our results show that the BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCov-19 (AstraZeneca), and Ad26.COV2.S COVID-19 (Janssen) vaccines elicited neutralizing antibody responses more than the BBIBP-CorV vaccine (Sinopharm) against B.1, C.36.3, and AY.32 (Delta) variants. While vaccines remain highly effective in managing the COVID-19 pandemic, ongoing monitoring of vaccine effectiveness is needed.
SARS-CoV-2 的多样性继续导致新的 SARS-CoV-2 变体的出现。SARS-CoV-2 抗体检测在通过确定中和抗体反应来管理 COVID-19 大流行方面至关重要。本研究旨在调查埃及接种疫苗的人群对 SARS-CoV-2 最常见变体的诱导抗体。从接种疫苗的参与者中采集血清样本，并使用微量中和测定法测定针对 SARS-CoV-2 变体的中和活性。我们的结果表明，BNT162b2（辉瑞-生物科技）、ChAdOx1 nCov-19（阿斯利康）和 Ad26.COV2.S COVID-19（杨森）疫苗对 B.1、C.36.3 和 AY.32（Delta）变体的中和抗体反应均高于 BBIBP-CorV 疫苗（国药）。虽然疫苗在管理 COVID-19 大流行方面仍然非常有效，但仍需要持续监测疫苗的有效性。
